AIM Vaccine Co., Ltd.

HKSE 6660.HK

AIM Vaccine Co., Ltd. Gross Profit Margin for the year ending December 31, 2023: -51.47%

AIM Vaccine Co., Ltd. Gross Profit Margin is -51.47% for the year ending December 31, 2023, a -163.31% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • AIM Vaccine Co., Ltd. Gross Profit Margin for the year ending December 31, 2022 was 81.30%, a -1.41% change year over year.
  • AIM Vaccine Co., Ltd. Gross Profit Margin for the year ending December 31, 2021 was 82.46%, a -0.25% change year over year.
  • AIM Vaccine Co., Ltd. Gross Profit Margin for the year ending December 31, 2020 was 82.67%, a 5.59% change year over year.
  • AIM Vaccine Co., Ltd. Gross Profit Margin for the year ending December 31, 2019 was 78.29%.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
HKSE: 6660.HK

AIM Vaccine Co., Ltd.

CEO Mr. Yan Zhou
IPO Date Oct. 6, 2022
Location China
Headquarters Building A, Gemdale Plaza
Employees 1,557
Sector Health Care
Industries
Vaccines Biotechnology Pharmaceuticals
Description

AIM Vaccine Co., Ltd. engages in the research and development, manufacturing, and commercialization of vaccine products for human use in the People's Republic of China. The company's product pipeline includes Bivalent Delta-Omicron BA.5 mRNA and Monovalent Omicron BA.5 mRNA, which is in phase III clinical trails for the treatment of COVID-19; EV71-CA16 Bivalent for HFMD; and Valent Pneumococcal Conjugate and Polysaccharide vaccine for pneumococcal disease. It also offers Hexavalent group B Streptococcus Polysaccharide Conjugate Vaccine for Group B strep disease; Diphtheria, Tetanus and Pertussis and Haemophilus In¬uenzae type B, and Diphtheria, Tetanus and Acellular Pertussis, and Absorbed Tetanus for DTP; Haemophilus In¬uenzae Type B for Hib; and freeze-dried human rabies and mRNA human rabies vaccine. In addition, the company develops Human Papillomavirus 2 and 3-valent vaccine; Tetravalent Meningococcal Conjugate vaccine; Tetravalent In¬uenzae vaccine; mRNA Shingles/Herpes Zoster vaccine; mRNA respiratory syncytial virus vaccine; live attenuated parotitis vaccine; and ACYW135 meningococcal polysaccharide vaccine. The company was formerly known as Beijing AIM Biological Vaccine Technology Group Co., Ltd. and changed its name to AIM Vaccine Co., Ltd. in September 2020. AIM Vaccine Co., Ltd. was incorporated in 2011 and is headquartered in Beijing, the People's Republic of China.

StockViz Staff

January 15, 2025

Any question? Send us an email